Welcome to our dedicated page for DAXOR news (Ticker: DXR), a resource for investors and traders seeking the latest updates and insights on DAXOR stock.
Daxor Corp (DXR) delivers critical advancements in blood volume measurement through its FDA-cleared BVA-100 technology. This page provides investors and healthcare professionals with centralized access to official news, financial updates, and clinical developments related to DXR’s diagnostic innovations.
Track press releases covering product milestones, peer-reviewed research validations, and strategic partnerships. Stay informed about quarterly earnings, regulatory filings, and advancements in fluid management diagnostics. All content is sourced directly from verified company communications to ensure accuracy.
Key updates include BVA-100 adoption metrics, clinical trial outcomes, and operational expansions. Bookmark this page for real-time insights into DXR’s role in transforming patient diagnostics through precise blood volume analysis. Regularly updated to serve as your primary resource for unbiased, factual Daxor Corp developments.
Daxor (Nasdaq: DXR), the global leader in blood volume measurement technology, announces its participation in the 45th International Society for Heart and Lung Transplant (ISHLT) Annual Meeting from April 27-30, 2025, in Boston, MA. The event, which attracts approximately 3,500 international specialists in advanced heart and lung disease treatment, will be held at the John B. Hynes Veterans Memorial Convention Center.
The company will showcase its blood volume analysis technology at Booth 305. According to CEO Michael Feldschuh, their diagnostic solution provides 98% accurate data for personalized treatment in both inpatient and outpatient settings, aimed at improving outcomes while reducing care duration and costs.
Daxor (DXR) announces its participation in the MedAxiom CV Transforum Spring'25 Conference in Orlando, FL from April 24-26, 2025. The event will feature a presentation by WellStar Health System's Dr. Brian Howard, highlighting their successful implementation of blood volume analysis (BVA) technology in reducing acute kidney injury rates following left ventricular assist device implantation.
The company's BVA-guided care has demonstrated significant improvements in patient outcomes according to peer-reviewed studies, including:
- 82% reduction in 30-day mortality
- 86% reduction in 1-year mortality
- 56% reduction in 30-day readmissions
- 55% reduction in length of stay when performed on admission
Daxor's BVA technology provides 98% accurate data for optimizing treatment plans and individualizing patient care, leading to improved outcomes and reduced care costs.
Daxor (DXR) announced significant research findings at the American College of Cardiology's 74th Annual Scientific Session, demonstrating improved survival rates in heart failure patients using their blood volume analysis (BVA) technology. The study, conducted by Minneapolis Heart Institute Foundation and Allina Health, analyzed 1,237 heart failure patients, with 202 receiving BVA testing near discharge.
Key findings revealed that patients confirmed as 'euvolemic' (normal blood volume) through BVA showed 2.61 times better survival rates compared to hypervolemic (congested) patients. The study demonstrated a strong statistical significance (p=0.002), and the correlation between blood volume status and survival persisted even after adjusting for comorbidities.
Daxor (Nasdaq: DXR) has submitted its next-generation blood volume analyzer, Daxor BVA, to the FDA for 510(k) approval. The new device represents a significant advancement in blood volume measurement technology, offering direct quantification of intravascular blood, red blood cell, and plasma volume.
The next-generation analyzer, developed under a U.S. Department of Defense contract, boasts several improvements over its predecessor, the BVA-100™ system, including:
- Three times faster processing
- Significantly simpler operation
- Complete portability
- Point of care analysis capabilities
These enhancements are designed to facilitate seamless integration of advanced blood volume diagnostics into clinical workflows, potentially improving medical care and patient outcomes.
Daxor (DXR) showcased significant presence at the American College of Cardiology's 74th Annual Scientific Session and Expo in Chicago. A key session on Blood Volume Analysis (BVA) versus pressure measurement attracted over 400 clinicians. Duke University Medical Center presented new research confirming BVA as a more precise measure of congestion in heart failure patients.
Dr. Marat Fudim of Duke University Health emphasized that pressure-based assessments often misrepresent true volume status. The Duke study revealed that common proxy markers including urine output, weight change, and biomarkers CA-125 and NT-proBNP did not correlate with intravascular volume. The findings reinforce that volume management, rather than pressure management, should be the primary focus in heart failure treatment.
Daxor (DXR) announces expansion of its blood volume analysis (BVA) technology to three regional healthcare facilities across the U.S. through its Tennessee-based ezBVA Lab service. The expansion includes:
- A Midwest academic medical center for outpatient cardiovascular care
- A Wisconsin primary health center for outpatient syncope assessment
- A Southern New Jersey cardiovascular care program for both inpatient and outpatient settings
The CLIA-certified ezBVA Lab delivers comprehensive BVA results within 24 hours, featuring 98% diagnostic accuracy for tailored fluid management. This expansion demonstrates the growing adoption of Daxor's technology in diverse healthcare settings, aimed at improving patient outcomes while reducing costs.
Daxor (DXR) reported significant growth in its fiscal year 2024, with its Net Asset Value (NAV) increasing to $7.25 per share from $7.08 in 2023. The company's operating division achieved remarkable results, including a 116.5% revenue increase year-over-year.
Key highlights include:
- 60.1% growth in diagnostic kit sales
- Addition of 12 new accounts in 2024
- Achievement of cash-flow break-even in Q1 2025
- Securing a $2.5M two-year Department of Defense contract
- Receiving over $350K in NIH and Launch Tennessee grants
The company is preparing to file for FDA approval of its next-generation blood volume analyzer through the 510(k) pathway. This new point-of-care system aims to enhance clinical workflows, particularly in critical care settings, and expand market opportunities in both hospital and outpatient environments.
Daxor (Nasdaq: DXR), the global leader in blood volume measurement technology, has scheduled an investor conference call for Thursday, March 6, 2025, at 4:30 p.m. ET. During the call, President and CEO Michael Feldschuh and CFO Robert Michel will present the company's fiscal year 2024 financial results and provide updates on corporate developments. The event will include a Q&A session, with investors having the option to submit questions in advance via email. A webcast replay will be available on Daxor.com following the call.
Daxor (DXR) reported significant progress in 2024 and early 2025, with notable financial and operational achievements. The company's net assets reached $36,789,893 ($7.25 per share) as of December 31, 2024, up from $34,010,384 ($7.08 per share) in 2023.
Key financial highlights include:
- Revenue growth of 116.5% year-over-year in 2024
- 60.1% increase in diagnostic system kit sales
- 12 new accounts in 2024 and 3 in early 2025
- Operating division achieved cash-flow break-even in Q1 2025
- Secured $2.5M DoD contract and $350K in additional funding
The company entered an agreement to acquire IP from its supplier for in-house manufacturing of Volumex and Glofil products. Daxor is preparing to resubmit FDA 510(k) application for its next-generation blood volume analyzer, which promises faster results and improved functionality. The company aims to transition from an investment company to an operating company designation by the end of 2025.
Daxor (DXR) reported significant progress in 2024 and early 2025, establishing itself as the global leader in blood volume measurement technology. The company achieved notable financial milestones, with net assets reaching $36,789,893 ($7.25 per share) as of December 31, 2024, up from $34,010,384 ($7.08 per share) in 2023.
Key achievements include:
- Revenue growth of 116.5% year-over-year in 2024
- 60.1% increase in diagnostic system kit sales
- 12 new accounts in 2024 and 3 in early 2025
- $2.5M DoD contract and $350K in grants from Launch Tennessee and NIH
- Operating division reached cash-flow break-even in Q1 2025
The company is preparing to launch its next-generation blood volume analyzer, which promises to be three times faster and simpler than current systems. Daxor also entered an agreement to acquire IP from its supplier to bring manufacturing in-house for Volumex and add Glo-fil to its product offerings.
